Kingsview Wealth Management LLC Has $24.68 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Kingsview Wealth Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 152,256 shares of the company’s stock after purchasing an additional 5,306 shares during the period. Kingsview Wealth Management LLC’s holdings in Johnson & Johnson were worth $24,675,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson in the first quarter valued at about $765,000. Beaird Harris Wealth Management LLC grew its stake in Johnson & Johnson by 19.1% in the first quarter. Beaird Harris Wealth Management LLC now owns 2,778 shares of the company’s stock valued at $439,000 after purchasing an additional 446 shares in the last quarter. Mount Yale Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 4.9% in the first quarter. Mount Yale Investment Advisors LLC now owns 22,051 shares of the company’s stock worth $3,488,000 after buying an additional 1,033 shares during the last quarter. QVR LLC acquired a new stake in shares of Johnson & Johnson in the first quarter worth about $478,000. Finally, Lavaca Capital LLC lifted its position in shares of Johnson & Johnson by 1.3% in the first quarter. Lavaca Capital LLC now owns 6,418 shares of the company’s stock worth $1,015,000 after buying an additional 85 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on JNJ shares. Citigroup boosted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.2 %

JNJ stock opened at $155.14 on Friday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $373.52 billion, a P/E ratio of 22.45, a P/E/G ratio of 2.76 and a beta of 0.53. The business’s 50 day moving average is $160.21 and its 200-day moving average is $156.21. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.66 EPS. Equities analysts anticipate that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.